GO Therapeutics is applying the latest advances in Glycobiology to create cancer drugs that are more potent and less toxic. Our “Hybrid Epitope” tumor-specific antibodies can be used in multiple modalities such as antibody-drug conjugates, bi-specific T-cell engagers, and immune-based cell therapies. GO Therapeutics’ team features some of the leading authorities in the science of the Cancer Glycoproteome.
- Constantine Theodoropulos Co-Founder and Chief Executive Officer
- Thayer White, PhD Co-Founder and Chief Scientific Officer
- Hans Wandall, MD, PhD Senior Scientific Consultant
- Henrik Clausen, SciD Senior Scientific Consultant